( PALO ALTO Calif.--(BUSINESS WIRE)--Apr...)Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients,Health

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 12, 2007 - Affymax, Inc. (Nasdaq:AFFY) today announced that results available from its Phase 2 clinical trial of Hematide(TM) dosed monthly in dialysis patients were presented this week at the National Kidney Foundation (NKF) 2007 Spring Clinical Meeting. The results from this maintenance-switch trial in patients previously treated with three-times weekly Epoetin Alfa (EPO) demonstrated that mean hemoglobin (Hgb) levels can be maintained at clinically acceptable levels following a switch to once-monthly treatments with Hematide at an appropriate dosing regimen. The data were presented by Anatole Besarab, M.D., adjunct professor of Medicine, Wayne State University and director of Clinical Research at Henry Ford Hospital, Detroit in a poster session at the NKF meeting.

"These data are encouraging and show that patients can be switched from a regimen of EPO three-times weekly to once monthly Hematide in a controlled fashion where hemoglobin levels were maintained within 1 g/dL of baseline at an appropriate dosing regimen," said Dr. Besarab. This is especially important given the growing concerns related to excessive hemoglobin increases due to erythropoiesis stimulating agent use."

"We believe these data support the once per month dosing of Hematide and warrant further investigation in pivotal clinical studies," added Anne-Marie Duliege, M.D., vice president, Clinical, Medical and Regulatory Affairs at Affymax. "Based on the entire Phase 2 data set and as a result of our end of Phase 2 meetings with the Food and Drug Administration (FDA), we are preparing for Phase 3 clinical trials in patients on dialysis and not on dialysis. We are currently in discussions with the FDA on the design of this Phase 3 program."

The Phase 2 trial, which involved 165 patients, was an open label, multi-dose study conducted to assess safety, pharmacodynamics and pharmacokinetics of
'"/>

Page: 1 2 3
Related medicine technology :

1. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
2. Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study